Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
Roering P, Siddiqui A, Heuser VD, Potdar S, Mikkonen P, Oikkonen J, Li Y, Pikkusaari S, Wennerberg K, Hynninen J, Grenman S, Huhtinen K, Auranen A, Carpén O, Kaipio K. Roering P, et al. Among authors: wennerberg k. Front Oncol. 2022 Aug 23;12:954430. doi: 10.3389/fonc.2022.954430. eCollection 2022. Front Oncol. 2022. PMID: 36081565 Free PMC article.
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K. Pietarinen PO, et al. Among authors: wennerberg k. Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146. Oncotarget. 2017. PMID: 28186983 Free PMC article.
Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.
Brodin BA, Wennerberg K, Lidbrink E, Brosjö O, Potdar S, Wilson JN, Ma L, Moens LN, Hesla A, Porovic E, Bernhardsson E, Papakonstantinou A, Bauer H, Tsagkozis P, von Sivers K, Wejde J, Östling P, Kallioniemi O, Stragliotto CL. Brodin BA, et al. Among authors: wennerberg k. Br J Cancer. 2019 Feb;120(4):435-443. doi: 10.1038/s41416-018-0359-4. Epub 2019 Feb 12. Br J Cancer. 2019. PMID: 30745580 Free PMC article.
ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K, Chen P, Roering P, Huhtinen K, Mikkonen P, Östling P, Lehtinen L, Mansuri N, Korpela T, Potdar S, Hynninen J, Auranen A, Grénman S, Wennerberg K, Hautaniemi S, Carpén O. Kaipio K, et al. Among authors: wennerberg k. J Pathol. 2020 Feb;250(2):159-169. doi: 10.1002/path.5356. Epub 2019 Dec 3. J Pathol. 2020. PMID: 31595974
Prediction of drug combination effects with a minimal set of experiments.
Ianevski A, Giri AK, Gautam P, Kononov A, Potdar S, Saarela J, Wennerberg K, Aittokallio T. Ianevski A, et al. Among authors: wennerberg k. Nat Mach Intell. 2019 Dec;1(12):568-577. doi: 10.1038/s42256-019-0122-4. Epub 2019 Dec 9. Nat Mach Intell. 2019. PMID: 32368721 Free PMC article.
162 results